Heparin-binding domain of IGFBP-2 in the treatment of metabolic disorders
US11192932B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2019 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | May 23, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/65
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.